Zennova Pharma Group Secures Nearly RMB 100 Million in Series B Funding to Drive Innovation and Set Industry Standards

VCBeat learned that recently, Zennova Pharma Group announced the completionNearly 100 Million USD in Series B Financing, which was exclusively invested by Hengbao Holdings. Meanwhile, Zennova Pharmaceuticals Group has successfully obtainedTens of Millions of YuanBank Credit. The funds from this round of financing will be used for the commercial batch production of the company's key products, market launch preparations, and the research and development of new products.

Internationalization is an important direction for the high-quality development of China's pharmaceutical industry. Facing the new situation of the reshaping of the global pharmaceutical innovation chain, industrial chain, and supply chain, we believe that by combining the powerful overseas market channels of Hengbao Holdings and the extensive experience of Zennova Pharmaceuticals Group's founding team in the development of new drugs, formulation production, and other aspects of the entire industrial chain, both parties will continue to enhance their comprehensive competitiveness and integrate at a higher level into the global pharmaceutical innovation and industrial system.

Regarding this round of financing, Guo Dahai, founder, chairman, and CEO of Zennova, stated:We are very grateful for the trust and support from Hengbao Holdings! 2023 is a year of full sprint for Zennova: continuously advancing the research, development, and production of high-end pharmaceuticals, increasing the introduction of products with high barriers and those filling domestic market gaps in China, and comprehensively implementing the electromechanical decoration and equipment installation projects at Zennova's Chengdu production base. These are important milestone tasks in Zennova's strategic development. We believe that, with the strong support of Hengbao Holdings and other shareholders, Zennova will continue to make breakthroughs in pharmaceutical industrialization, internationalization, and marketization, enhance its core competitiveness, and initiate new growth points. We aim to achieve these goals within the next three years."A three-pronged profit model with synchronized cash flows: 'R&D and production in the U.S. - sales in the U.S., R&D and production in China - international sales, R&D and production in China - sales in China.'"

Zennova Pharma Group is an innovative international pharmaceutical company group with three strategic focuses: Made in China, global research and development, and global markets. It concentrates on four major therapeutic areas: ophthalmology, virology, cardiovascular, and oncology. Zennova Pharma currently has R&D bases in New York and New Jersey, a contract manufacturing plant in Chicago, and an all-formulation international formulation center in Chengdu that integrates R&D, production, and sales. The company possesses the Liquipuls™ comprehensive new drug development technology platform, which has been meticulously researched for 20 years in the United States and is globally original.

Zennova Pharma Group, since its establishment in 2018, has consistently adhered to the core concept of a global perspective and operations in both China and the U.S. The company’s product development is primarily carried out by Zennova in the United States, while commercial batch production and marketing will first be implemented in the U.S. Zennova Pharmaceuticals Group, located in Chengdu Tianfu International Bio City, is building an international formulation center with all dosage forms. Currently, the first phase of construction, covering a total of 30,000 square meters, has been completed. The entire interior decoration and equipment installation and debugging are expected to be finished by September this year, with the transfer of technology for a series of FDA-approved drugs scheduled to begin in the fourth quarter. This center is built according to international quality standards, and its products meet the standards of the U.S. FDA, EU EMA, and Chinese quality requirements. In the next three years, the company will market several drugs in both the Chinese and American markets as well as globally.

Zennova will always adhere to the core values of "Commitment to Life, Scaling Pharmaceutical Peaks" (Innovation for better medicine). Not only does it develop high-level products in accordance with world standards represented by the FDA, but it also produces high-quality products in line with international standards. Zennova drives the internationalization of China's pharmaceuticals, making effective and innovative medicines for the cause of human health!